Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis
Top Cited Papers
Open Access
- 29 December 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 39 (2), 306-318
- https://doi.org/10.1093/schbul/sbr148
Abstract
Individuals with schizophrenia have high levels of medical comorbidity and cardiovascular risk factors. The presence of 3 or more specific factors is indicative of metabolic syndrome, which is a significant influence upon future morbidity and mortality. We aimed to clarify the prevalence and predictors of metabolic syndrome (MetS) in adults with schizophrenia and related disorders, accounting for subgroup differences. A PRISMA systematic search, appraisal, and meta-analysis were conducted of 126 analyses in 77 publications (n = 25 692). The overall rate of MetS was 32.5% (95% CI = 30.1%–35.0%), and there were only minor differences according to the different definitions of MetS, treatment setting (inpatient vs outpatient), by country of origin and no appreciable difference between males and females. Older age had a modest influence on the rate of MetS (adjusted R2 = .20; P < .0001), but the strongest influence was of illness duration (adjusted R2 = .35; P < .0001). At a study level, waist size was most useful in predicting high rate of MetS with a sensitivity of 79.4% and a specificity of 78.8%. Sensitivity and specificity of high blood pressure, high triglycerides, high glucose and low high-density lipoprotein, and age (>38 y) are shown in supplementary appendix 2 online. Regarding prescribed antipsychotic medication, highest rates were seen in those prescribed clozapine (51.9%) and lowest rates of MetS in those who were unmedicated (20.2%). Present findings strongly support the notion that patients with schizophrenia should be considered a high-risk group. Patients with schizophrenia should receive regular monitoring and adequate treatment of cardio-metabolic risk factors.Keywords
This publication has 68 references indexed in Scilit:
- Endogenic and Iatrogenic Diabetes Mellitus in Drug-naïve Schizophrenia: The Role of Olanzapine and its Place in the Psychopharmacological Treatment AlgorithmNeuropsychopharmacology, 2011
- Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysisSchizophrenia Research, 2010
- Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia PatientsNeuropsychopharmacology, 2010
- Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health AdministrationBMC Psychiatry, 2009
- Harmonizing the Metabolic SyndromeCirculation, 2009
- Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)European Psychiatry, 2009
- Metabolic profile of antipsychotic-naive individuals with non-affective psychosisThe British Journal of Psychiatry, 2009
- Physical illness and schizophrenia: a review of the literatureActa Psychiatrica Scandinavica, 2007
- A systematic review of mortality in schizophrenia - Is the differential mortality gap worsening over time?Archives of General Psychiatry, 2007
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986